Selective suppression of cocaine- Versus food-maintained responding by monoamine releasers in rhesus monkeys: Benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 1, 2009, Pages 272-281

  Negus, S S ^a,b   Baumann, M H ^c   Rothman, R B ^c   Mello, N K ^b   Blough, B E ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b MCLEAN HOSPITAL   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZYLPIPERIDINE; BENZYLPIPERAZINE; COCAINE; DOPAMINE; PHENMETRAZINE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; FOOD INTAKE; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEROTONIN RELEASE;

ANIMALS; BIOGENIC MONOAMINES; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; COCAINE-RELATED DISORDERS; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DOPAMINE; DOPAMINE UPTAKE INHIBITORS; FOOD; MACACA MULATTA; MALE; NOREPINEPHRINE; PHENMETRAZINE; PIPERAZINES; PIPERIDINES; REWARD; SEROTONIN; SYNAPTOSOMES;

EID: 63849126584     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.143701     Document Type: Article

References (41)

1. Baumann MH, Ayestas MA, Dersch CM, Brockington A, Rice KC, and Rothman RB (2000) Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse 36:102113.
2. Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, and Rothman RB (2005) N-Substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or "Ecstasy"). Neuropsy-chopharmacology 30:550-560.
3. Baumann MH and Rothman RB (1998) Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans. Biol Psychiatry 44:578-591.
4. Chait LD, Uhlenhuth EH, and Johanson CE (1987) Reinforcing and subjective effects of several anorectics in normal human volunteers. J Pharmacol Exp Ther 242:777-783.
5. Corwin RL, Woolverton WL, Schuster CR, and Johanson CE (1987) Anorectics:effects on food intake and self-administration in rhesus monkeys. Alcohol Drug Res 7:351-361.
6. Czoty PW, Ginsburg BC, and Howell LL (2002) Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 300:831-837.
7. de la Garza R and Johanson CE (1987) Discriminative stimulus properties ofintra-gastrically administered d-amphetamine and pentobarbital in rhesus monkeys. J Pharmacol Exp Ther 243:955-962.
8. Do Carmo GP, Mello NK, Rice KC, Folk JE, and Negus SS (2006) Effects of the selective delta opioid agonist SNC80 on cocaine- and food-maintained responding in rhesus monkeys. Eur J Pharmacol 547:92-100.
9. Fantegrossi WE, Winger G, Woods JH, Woolverton WL, and Coop A(2005) Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluorometh-ylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend 77:161-168.
10. Gold LH, Geyer MA, and Koob GF (1989) Neurochemical mechanisms involved in behavioral effects of amphetamines and related designer drugs. NIDA Res Monogr 94:101-126.
11. Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, and Moeller FG (2001) Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 21:522-526.
12. Grabowski J, Shearer J, Merrill J, and Negus SS (2004) Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29:1439 -1464.
13. Griffiths RR, Winger G, Brady JV, and Snell JD (1976) Comparison of behavior maintained by infusions of eight phenylethylamines in baboons. Psychopharma-cology (Berl) 50:251-258.
14. Haney M and Spealman R (2008) Controversies in translational research: drug self-administration. Psychopharmacology (Berl) 199:403-419.
15. Hoffman B(2001) Catecholamines, sympathomimeticdrugs, andadrenergic receptor antagonists, in The Pharmacological Basis of Therapeutics (Hardman JG and Limbird LE eds) pp 215-268, McGraw-Hill, New York.
16. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
17. Jasinski D and Krishnan S (2008) Human pharmacology of intravenous lisdexam-fetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol doi:10.1177/0269881108093841.
18. Jones CN, Howard JL, and McBennett ST (1980) Stimulus properties of antidepressants in the rat. Psychopharmacology (Berl) 67:111-118.
19. Mello NK and Negus SS (1996) Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14:375-424.
20. Mello NK and Negus SS (1998) Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286:812-824.
21. Mello NK, Negus SS, Rice KC, and Mendelson JH (2006) Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys. Pharmacol Biochem Behav 85:744-751.
22. Negus SS (2003) Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupentixol. Neuropsychopharmacology 28:919 -931.
23. Negus SS, Brandt MR, and Mello NK (1999) Effects of the long-acting monoamine reuptake inhibitor indatraline on cocaine self-administration in rhesus monkeys. JPharmacol Exp Ther 291:60-69.
24. Negus SS and Mello NK (2002) Effects of mu-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of mu-agonist efficacy. J Pharmacol Exp Ther 300:1111-1121.
25. Negus SS and Mello NK (2003a) Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology (Berl) 167:324-332.
26. Negus SS and Mello NK (2003b) Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend 70:39 -52.
27. Negus SS, Mello NK, Blough BE, Baumann MH, and Rothman RB (2007) Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther 320:627-636.
28. Negus SS, Mello NK, Kimmel HL, Howell LL, and Carroll FI (2009) Effects of the monoamine uptake inhibitors RTI-112 and RTI-113 on cocaine- and food-maintained responding in rhesus monkeys. Pharmacol Biochem Behav 91:333-338.
29. Negus SS, Mello NK, Lamas X, and Mendelson JH (1996) Acute and chronic effects of flupentixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 278:879 -890.
30. Negus SS, Mello NK, Portoghese PS, and Lin CE (1997) Effects ofkappa opioids on cocaine self-administration byrhesus monkeys. JPharmacol ExpTher282:44-55.
31. Peltier RL, Li DH, Lytle D, Taylor CM, and Emmett-Oglesby MW (1996) Chronic d-amphetamine or methamphetamine produces cross-tolerance to the discriminative and reinforcing stimulus effects of cocaine. J Pharmacol Exp Ther 277:212-218.
32. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, and Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41.
33. Rothman RB, Blough BE, and Baumann MH (2002a) Appetite suppressants as agonist substitution therapies for stimulant dependence. Ann N Y Acad Sci 965:109-126.
34. Rothman RB, Blough BE, and Baumann MH (2007) Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J 9:E1-E10.
35. Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, and Baumann MH (2005) Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther 313:1361-1369.
36. Rothman RB, Katsnelson M, Vu N, Partilla JS, Dersch CM, Blough BE, and Baumann MH (2002b) Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol 447:51-57.
37. Rush CR, Stoops WW, and Hays LR (2009) Cocaine effects during D-amphetamine maintenance: a human laboratoryanalysisofsafety, tolerabilityand efficacy. Drug Alcohol Depend 99:261-271.
38. Silverstone T (1992) Appetite suppressants: a review. Drugs 43:820-836.
39. Vocci FJ and Elkashef A (2005) Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr Opin Psychiatry 18:265-270.
40. Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, and Woolverton WL (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313:848-854.
41. Wood DM and Emmett-Oglesby MW (1988) Substitution and cross-tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine. Psychopharmacology (Berl) 95:364-368.